Validation and Clinical Utility of ELISA Methods for Quantification of Amyloid-β of Peptides in Cerebrospinal Fluid Specimens from Alzheimer’s Disease Studies

• Published in: Journal of Alzheimer's disease Vol. 45; no. 2; p. 527
• Main Authors: Lachno, D Richard, Evert, Barbara A, Maloney, Kaia, Willis, Brian A, Talbot, Jayne A, Vandijck, Manu, Dean, Robert A
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2015
• Subjects: Alzheimer Disease - cerebrospinal fluid; Amyloid beta-Peptides - cerebrospinal fluid; Cerebrospinal Fluid - drug effects; Cerebrospinal Fluid - metabolism; Enzyme-Linked Immunosorbent Assay; Female; Heterocyclic Compounds, 2-Ring - pharmacology; Humans; Male; Peptide Fragments - cerebrospinal fluid; Picolinic Acids - pharmacology; Polysorbates - pharmacology; Psychiatric Status Rating Scales; Reproducibility of Results; Surface-Active Agents - pharmacology; Time Factors

The aim of this study was to validate assays for measurement of amyloid-β (Aβ) peptides in cerebrospinal fluid (CSF)specimens according to regulatory guidance and demonstrate their utility with measurements in specimens from Alzheimer’s disease (AD) studies. Methods based on INNOTEST(®)β-AMYLOID(1-4...